Drug Profile
MGD 007
Alternative Names: MGD-007Latest Information Update: 19 May 2021
Price :
$50
*
At a glance
- Originator MacroGenics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 31 Dec 2020 Discontinued - Phase-I for Colorectal cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) before December 2020
- 31 Dec 2020 Discontinued - Phase-I/II for Colorectal cancer (Combination therapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (IV) before December 2020
- 28 Mar 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)